Clinical efforts have been made to develop new lung cancer therapies targeting HER/HER2-PI3K-Akt-NF-κB signaling using novel inhibitors of this pathway, such as lapatinib and bortezomib (27,29–32). Here, AKT1 is linked to lung carcinoma.